← Medication & Supplement Reference

VETERINARY TEAM REFERENCE · MEDICATION

Sarolaner + moxidectin + pyrantel

Updated October 27, 2026 · Sources and review status below

For veterinarians and veterinary staff. Product-label information is distinct from extra-label clinical practice. This is not a complete prescribing formulary or an automated interaction screen. Verify the current label, exact formulation, patient and species-specific clinical reference before use. Independent veterinary/pharmacy review remains pending.

Prescribing overview

Simparica Trio combines flea/tick, heartworm-prevention and selected intestinal-worm coverage. It differs from single-ingredient Simparica and requires the correct age and weight presentation.

Combination antiparasiticProduct-specific clinical reference

Simparica Trio combines flea/tick, heartworm-prevention and selected intestinal-worm coverage. It differs from single-ingredient Simparica and requires the correct age and weight presentation.

Key prescribing checks

  • Confirm the indication, route, current weight, disease status and concurrent treatments before prescribing.

Uses by species

Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.

Dogs

FDA-approved canine product

Heartworm prevention; labeled flea/tick and roundworm/hookworm control; specified vector-mediated infection prevention

US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.

Use / indication source ↗

Pharmacology & pharmacokinetics

Mechanism and clinical role

Sarolaner targets arthropod chloride channels; moxidectin targets susceptible nematodes; pyrantel causes susceptible intestinal nematode paralysis.

Absorption, distribution, metabolism and elimination

Sarolaner and moxidectin are systemically absorbed and largely eliminated through bile; formulation-specific studies do not establish another product’s interchangeability.

SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC

Contraindications & cautions

Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.

Simparica Trio

US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.

Contraindications · when not to use

  • The reviewed label reports no known contraindications; precautions and eligibility restrictions still apply.

Precautions & monitoring

  • Caution with neurologic disease. Test for existing heartworms; this is not adult-heartworm treatment. Reproductive safety was not evaluated.

Selected product information; this is not a complete interaction or patient-specific prescribing assessment.

Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.

Adverse effects

Vomiting, diarrhea and lethargy were reported. Isoxazoline-associated neurologic effects include tremor, ataxia and seizures, including without prior seizures.

These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.

Dosing & administration

Verify the source before prescribing. The regimens below summarize selected veterinary product labels, not every accepted veterinary use. They are not automatic substitutions between brands or formulations. Renal/hepatic disease, concurrent therapy, age, indication and clinical response can require a different plan.

A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.

No numeric regimen is supplied in this entry. The veterinarian must consult the exact current product label; this entry does not enable a dosing calculator.

Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗

Drug & supplement interactions

This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.

Compare with other medications and check species →

Simparica Trio

US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.

  • No universal compatibility conclusion follows from the label. Check overlapping antiparasitic ingredients and the complete treatment plan.
Interaction source ↗Interaction source ↗Interaction source ↗

Monitoring

Verify heartworm testing, weight-band selection, full ingestion, parasite-control response and neurologic changes.

Client counseling

Record administration dates and review missed doses with the veterinarian. Preventing flea-vectored tapeworm infection does not treat established tapeworms.

This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.

Storage & handling

Follow the current package storage instructions.

Brands, formulations & ingredient identity

Active ingredients

Sarolaner · Moxidectin · pyrantel pamoate

Other searchable names: Simparica Trio

This reference is limited to the named product and presentation; matching ingredients do not establish interchangeability.

Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.

Simparica Trio

Formulation
Canine chewable tablets
Label / product scope
Dogs

US dogs at least eight weeks old and 2.8 lb; exact parasite species and life stages are limited to current labeling.

Product label / source ↗

References & review status

Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.

Search another medication or supplement →

CONTINUE EXPLORING

Use these connected guides to prepare informed questions for your veterinary team.

Find Veterinary Care Near YouLocate general practices, urgent-care clinics, emergency hospitals and specialists.Read resource →When It Is an EmergencyRecognize signs that require immediate veterinary care.Read resource →Interactive Symptom NavigatorStart with what you notice and understand when to seek help.Read resource →Poisons and Household HazardsRecognize common exposures and avoid unsafe home treatment.Read resource →Printable Owner ToolkitBring observations, medication details and questions to your appointment.Read resource →
Privacy & cookie choices